RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)
In 2013, Russia registered officially the indications for the use of monoclonal antibodies to B-lymphocytes (rituximab, RTM) in systemic vasculitides associated with antineutrophil cytoplasmic antibodies (ANCA-SV). This communication presents the preliminary results of the Russian register of the RT...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2014-06-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1918 |
| _version_ | 1797862790503858176 |
|---|---|
| author | T. V. Beketova E. N. Aleksandrova T. M. Novoselova E. G. Sazhina E. V. Nikolaeva A. V. Smirnov V. N. Sorotskaya E. V. Zemerova I. F. Nam N. M. Nikitina G. S. Arkhangelskaya Z. R. Bagautdinova I. N. Dashkov S. Yu. Chernykh O. V. Zhirnova Yu. A. Lushpaeva L. V. Masneva I. P. Afanasieva A. E. Arseniev I. V. Kondratenko I. B. Bashkova S. I. Glukhova E. L. Nasonov |
| author_facet | T. V. Beketova E. N. Aleksandrova T. M. Novoselova E. G. Sazhina E. V. Nikolaeva A. V. Smirnov V. N. Sorotskaya E. V. Zemerova I. F. Nam N. M. Nikitina G. S. Arkhangelskaya Z. R. Bagautdinova I. N. Dashkov S. Yu. Chernykh O. V. Zhirnova Yu. A. Lushpaeva L. V. Masneva I. P. Afanasieva A. E. Arseniev I. V. Kondratenko I. B. Bashkova S. I. Glukhova E. L. Nasonov |
| author_sort | T. V. Beketova |
| collection | DOAJ |
| description | In 2013, Russia registered officially the indications for the use of monoclonal antibodies to B-lymphocytes (rituximab, RTM) in systemic vasculitides associated with antineutrophil cytoplasmic antibodies (ANCA-SV). This communication presents the preliminary results of the Russian register of the RTM application in autoimmune diseases (NORMA) that has included 50 patients with ANCA-SV treated in 14 cities of the Russian Federation. Twenty-five of 50 (50%) patients received repeated courses of RTM. RTM has demonstrated a high efficacy and a good profile of treatment safety in patients with ANCA-SV in real-life national clinical practice. Among 25 patients who had been followed up for over 12 months, the remission was achieved in 92% of cases, a decrease in the ANCA-SV activity was observed in 8%. The efficacy of RTM increased when performing repeated courses, while it has been noted that the positive results can be obtained by prescribing a repeated course of RTM at a reduced dose (500–1000 mg). Prescription of the repeated courses was primarily required in patients with granulomatosis and polyangiitis affecting the lungs. Care should be taken when combining RTM treatment with cytostatics (primarily with cyclophosphamide) because of the risk of secondary immunodeficiency and infectious adverse events (AE), which have been the most frequent serious AE (12%) in patients with ANCA-SV. |
| first_indexed | 2024-04-09T22:25:15Z |
| format | Article |
| id | doaj.art-7eb2291aa58140549bd57c8bfa889109 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:25:15Z |
| publishDate | 2014-06-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-7eb2291aa58140549bd57c8bfa8891092023-03-22T13:45:49ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922014-06-0152214715810.14412/1995-4484-2014-147-1581853RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA)T. V. Beketova0E. N. Aleksandrova1T. M. Novoselova2E. G. Sazhina3E. V. Nikolaeva4A. V. Smirnov5V. N. Sorotskaya6E. V. Zemerova7I. F. Nam8N. M. Nikitina9G. S. Arkhangelskaya10Z. R. Bagautdinova11I. N. Dashkov12S. Yu. Chernykh13O. V. Zhirnova14Yu. A. Lushpaeva15L. V. Masneva16I. P. Afanasieva17A. E. Arseniev18I. V. Kondratenko19I. B. Bashkova20S. I. Glukhova21E. L. Nasonov22V.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaMedical Institute, Tula State University, Tula, RussiaCounty Clinical Hospital, Khanty-Mansiysk, RussiaV.I. Razumovsky State Medical University, Ministry of Health of Russia, SaratovV.I. Razumovsky State Medical University, Ministry of Health of Russia, SaratovSamara City Hospital Four, SamaraRepublican Clinical and Diagnostic Center, Ministry of Health of the Udmurt Republic, IzhevskBryansk Regional Hospital One, BryanskIrkutsk City Clinical Hospital One, IrkutskTver Regional Clinical Hospital, TverTyumen Regional Rheumatology Center, Regional Clinical Hospital One, TumenSaint Ioasaf Belgorod Regional Clinical Hospital, BelgorodIvanovo Regional Clinical Hospital, IvanovoIvanovo Regional Clinical Hospital, IvanovoRussian Children’s Clinical Hospital, Ministry of Health of Russia, MoscowI.N. Ulyanov Chuvash State University, CheboksaryV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaV.A. Nasonova Research Institute of Rheumatology of the Russian Academy of Medical Sciences, Moscow, RussiaIn 2013, Russia registered officially the indications for the use of monoclonal antibodies to B-lymphocytes (rituximab, RTM) in systemic vasculitides associated with antineutrophil cytoplasmic antibodies (ANCA-SV). This communication presents the preliminary results of the Russian register of the RTM application in autoimmune diseases (NORMA) that has included 50 patients with ANCA-SV treated in 14 cities of the Russian Federation. Twenty-five of 50 (50%) patients received repeated courses of RTM. RTM has demonstrated a high efficacy and a good profile of treatment safety in patients with ANCA-SV in real-life national clinical practice. Among 25 patients who had been followed up for over 12 months, the remission was achieved in 92% of cases, a decrease in the ANCA-SV activity was observed in 8%. The efficacy of RTM increased when performing repeated courses, while it has been noted that the positive results can be obtained by prescribing a repeated course of RTM at a reduced dose (500–1000 mg). Prescription of the repeated courses was primarily required in patients with granulomatosis and polyangiitis affecting the lungs. Care should be taken when combining RTM treatment with cytostatics (primarily with cyclophosphamide) because of the risk of secondary immunodeficiency and infectious adverse events (AE), which have been the most frequent serious AE (12%) in patients with ANCA-SV.https://rsp.mediar-press.net/rsp/article/view/1918systemic vasculitis associated with neutrophil cytoplasmic antibodieswegener's granulomatosis with polyangiitismicroscopic polyangiitiseosinophilic granulomatosis with polyangiitis (churg-strauss syndrom)biological anti-b cell therapyrituximab |
| spellingShingle | T. V. Beketova E. N. Aleksandrova T. M. Novoselova E. G. Sazhina E. V. Nikolaeva A. V. Smirnov V. N. Sorotskaya E. V. Zemerova I. F. Nam N. M. Nikitina G. S. Arkhangelskaya Z. R. Bagautdinova I. N. Dashkov S. Yu. Chernykh O. V. Zhirnova Yu. A. Lushpaeva L. V. Masneva I. P. Afanasieva A. E. Arseniev I. V. Kondratenko I. B. Bashkova S. I. Glukhova E. L. Nasonov RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA) Научно-практическая ревматология systemic vasculitis associated with neutrophil cytoplasmic antibodies wegener's granulomatosis with polyangiitis microscopic polyangiitis eosinophilic granulomatosis with polyangiitis (churg-strauss syndrom) biological anti-b cell therapy rituximab |
| title | RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA) |
| title_full | RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA) |
| title_fullStr | RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA) |
| title_full_unstemmed | RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA) |
| title_short | RUSSIAN EXPERIENCE WITH USING MONOCLONAL ANTIBODIES TO B-LYMPHOCYTES (RITUXIMAB) IN SYSTEMIC VASCULITIDES ASSOCIATED WITH NEUTROPHIL CYTOPLASMIC ANTIBODIES (PRELIMINARY RESULTS OF THE RUSSIAN REGISTER NORMA) |
| title_sort | russian experience with using monoclonal antibodies to b lymphocytes rituximab in systemic vasculitides associated with neutrophil cytoplasmic antibodies preliminary results of the russian register norma |
| topic | systemic vasculitis associated with neutrophil cytoplasmic antibodies wegener's granulomatosis with polyangiitis microscopic polyangiitis eosinophilic granulomatosis with polyangiitis (churg-strauss syndrom) biological anti-b cell therapy rituximab |
| url | https://rsp.mediar-press.net/rsp/article/view/1918 |
| work_keys_str_mv | AT tvbeketova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT enaleksandrova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT tmnovoselova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT egsazhina russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT evnikolaeva russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT avsmirnov russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT vnsorotskaya russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT evzemerova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT ifnam russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT nmnikitina russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT gsarkhangelskaya russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT zrbagautdinova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT indashkov russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT syuchernykh russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT ovzhirnova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT yualushpaeva russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT lvmasneva russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT ipafanasieva russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT aearseniev russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT ivkondratenko russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT ibbashkova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT siglukhova russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma AT elnasonov russianexperiencewithusingmonoclonalantibodiestoblymphocytesrituximabinsystemicvasculitidesassociatedwithneutrophilcytoplasmicantibodiespreliminaryresultsoftherussianregisternorma |